Semaglutide (brand names Ozempic and Wegovy) is a long-acting GLP-1 receptor agonist used for type 2 diabetes and weight management
The demand for glucagon-like peptide-1 (GLP-1) medications like Wegovy, Ozempic, Zepbound, and Mounjaro has surged in recent years, driven by their effectiveness for weight loss, blood sugar control, and the reduction of major cardiovascular events
Everyone who needs these medicines should be able to access and afford them, regardless of where they live or their financial situation
L-Carnitine is essential for heart and brain function, muscle mobility, and a range of other critical body processes
In no way should any QSR overcorrect and pivot fully into the GLP-1 craze they should simply realize that GLP-1 users are a new segment of the population that must be understood and to whom marketing dollars should be allocated